Self-assembled Graphene-dextran Nanohybrids For Efficient Drug Release In Drug-resistent Cancer Cells

Graphene is a kind of single chip structure of the new material build by carbonatoms. Graphene oxide (GO), one of the most important graphene derivatives,Graphene is caused by such a great influence, mainly due to it has rich hydroxyl andcarboxyl oxygen group on the surface of GO, make its have good high-solubility inwater, easy functionalization and low toxicity. Graphene Oxide (GO) as nano-drug carrierhas broad application, because of its unique structure and properties, but easilycompared in salt and serum, thus limiting the GO applications in the fields of biology.Also we must pay attention to functionalization GO on drug loading, release andtoxicity, need to further system study. Therefore, this paper studies the system GOmodification, typical cancer drugs DOX adsorption and release on GO, and thecellular toxicity.NGO were prepared by modified Hummer method, because NGO easilycompared in salt and serum, we need to improve its stability. We have demonstrateda new noncovalent “π-π interaction” approach for the modification of NGO withhematin-conjugated dextran (HDex), which has better biocompatibility as comparedto native NGO. By comprehensive testing and characterization the water-soluble,stability, toxicity, drug-loading efficiency. By adjusting the different of NGO andHDex ratio, study the changes of their stability and toxicity.Reaearch shows that use hematin-conjugated dextran (HDex), not onl has goodstability, but also has the very high load capacity than native NGO, Anti-cancer drugDOX can be efficetively loaded in NGO-HDex with a high loading capacity of3.4mg/mg NGO. NGO-HDex loaded anti-cancer drug DOX release behaviour ispH-dependent. The release speed in weak acidity solution is faster than in neutral. Aswe all know, cancer tissue surrounding partial weak acidity, so DOX can selectiverelease. Cells experiments shows that: use the NGO-HDex load DOX can moreeffectively kill resistant cell than free DOX. These results thus suggest that NGO-HDex has a high potential as a drug nanocarrier for cancer therapy.